Addressing the Cardiometabolic Risk Continuum in Metabolic dysfunction-associated steatohepatitis (MASH): What Clinicians Need to Know

Addressing the Cardiometabolic Risk Continuum in Metabolic dysfunction-associated steatohepatitis (MASH): What Clinicians Need to Know is organized by Tarsus CNS.

Course Opens: 04/03/2025
Course Expires: 04/03/2026

Description:
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex condition rooted in metabolic disturbances and often coexists with obesity, prediabetes, type 2 diabetes, and cardiovascular disease. Stemming from metabolic dysfunction-associated steatotic liver disease (MASLD), MASH is closely linked to cardiometabolic risk factors and pre-existing cardiovascular conditions. MASH is a gradually advancing and often asymptomatic liver disease that necessitates early detection and diagnosis. Despite its widespread prevalence and the existence of established evidence and guidelines, the screening and management of MASH remain insufficient among health care professionals.

Join us for an interactive online CME activity that combines insightful talks from an expert on MASH diagnosis and treatment with escape room challenges. Acquire advanced knowledge from top faculty, then challenge yourself in virtual, case-based escape rooms where you’ll solve clinical puzzles, address real patient scenarios, and implement key concepts interactively. This immersive experience not only enhances learning but also strengthens crucial decision-making skills, making the process of earning CME credits both educational and enjoyable.

Learning Objectives:
After completing this activity, the participant should be better able to:

• Explain MAFLD/MASH pathogenesis and the role that cardiovascular and cardiometabolic risk factors, including obesity and diabetes, play in MASH progression in order to improve the identification of MASH 
• Recognize current and emerging approaches and tools to screen and diagnose MAFLD and MASH in clinical practice 
• Summarize the current guidelines and recommendations for treatment of MASH, including recent consensus statements 
• Review the rationale, efficacy and safety of GLP-1 RAs for the treatment of MASH 
• List emerging MASH pharmacotherapies that aim to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression.